Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA) Targeting Submission of NDA for LIQ861 in 1Q 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that third quarter 2019 financial results will be reported on Wednesday, November 13, 2019 .
RESEARCH TRIANGLE PARK, N.C. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin , Vice President of Global Commercial Development at
RESEARCH TRIANGLE PARK, N.C. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the
RESEARCH TRIANGLE PARK, N.C. , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin , M.B., Ch.B., to the Company’s Board of Directors (the
RESEARCH TRIANGLE PARK, N.C. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the H.C.
RESEARCH TRIANGLE PARK, N.C. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the 2019
On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Aug.
RESEARCH TRIANGLE PARK, N.C. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology , today announced
RESEARCH TRIANGLE PARK, N.C. , June 26, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology,
